The effect of snuff (smokeless tobacco) on disease activity and function in rheumatoid arthritis: Experiences from the better anti-rheumatic farmacotherapy, a longitudinal multicenter study on early rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 19, Issue 1, 2013, Pages 14-18

  Andersson, Maria L E ^a   Bergman, Stefan ^b   Söderlin, Maria K ^a  

^a Spenshult Rheumatology Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

epidemiology; Rheumatoid arthritis; smokeless tobacco; snuff

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; GLUCOCORTICOID;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SMOKELESS TOBACCO; SMOKING; SOCIAL CLASS; SOCIAL STATUS; SWEDEN; VISUAL ANALOG SCALE;

ADULT; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SWEDEN; TOBACCO USE DISORDER; TOBACCO, SMOKELESS;

EID: 84874187791     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31828214ed     Document Type: Article

References (32)

1. Kallberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet. 2007;80:867-875.
2. Soderlin MK, Petersson IF, Bergman S, et al. Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA. Scand J Rheumatol. 2011;40:249-255.
3. Soderlin MK, Bergman S. Absent "Window of Opportunity" in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis. J Rheumatol. 2011;38:2160-2168.
4. Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis. 2011;70:469-475.
5. Saevarsdottir S, Wedren S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011;63:26-36.
6. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558-1565.
7. Abhishek A, Butt S, Gadsby K, et al. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol. 2010;16:15-18.
8. Mattey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol. 2009;36:1180-1187.
9. Söderlin M, Petersson I, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41:1-9.
10. Manfredsdottir VF, Vikingsdottir T, Jonsson T, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford). 2006;45:734-740.
11. Papadopoulos NG, Alamanos Y, Voulgari PV, et al. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol. 2005;23:861-866.
12. Saag KG, Cerhan JR, Kolluri S, et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis. 1997;56:463-469.
13. Naranjo A, Toloza S, Guimaraes da Silveira I, et al. Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. Clin Exp Rheumatol. 2010;28:820-827.
14. Maska LB, Sayles HR, O'Dell JR, et al. Serum cotinine as a biomarker of tobacco exposure is not associated with treatment response in early rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64: 1804-1810.
15. Zia S, Ndoye A, Nguyen VT, et al. Nicotine enhances expression of the alpha 3, alpha 4, alpha 5, and alpha 7 nicotinic receptors modulating calcium metabolism and regulating adhesion and motility of respiratory epithelial cells. Res Commun Mol Pathol Pharmacol. 1997;97:243-262.
16. van Maanen MA, Lebre MC, van der Poll T, et al. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum. 2009;60:114-122.
17. Lindblad SS, Mydel P, Jonsson IM, et al. Smoking and nicotine exposure delay development of collagen-induced arthritis in mice. Arthritis Res Ther. 2009;11:R88.
18. Osterdahl BG, Jansson C, Paccou A. Decreased levels of tobacco-specific N-nitrosamines in moist snuff on the Swedish market. J Agric Food Chem. 2004;52:5085-5088.
19. Zahm SH, Heineman EF, Vaught JB. Soft tissue sarcoma and tobacco use: data from a prospective cohort study of United States veterans. Cancer Causes Control. 1992;3:371-376.
20. Henley SJ, Thun MJ, Connell C, et al. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control. 2005;16:347-358.
21. Bolinder G, Alfredsson L, Englund A, et al. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health. 1994;84:399-404.
22. Janzon E, Hedblad B. Swedish snuff and incidence of cardiovascular disease. A population-based cohort study. BMC Cardiovasc Disord. 2009;9:21.
23. Hansson J, Pedersen NL, Galanti MR, et al. Use of snus and risk for cardiovascular disease: results from the Swedish Twin Registry. J Intern Med. 2009;265:717-724.
24. Gupta PC, Ray CS. Smokeless tobacco and health in India and South Asia. Respirology. 2003;8:419-431.
25. Carlens C, Hergens MP, Grunewald J, et al. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am J Respir Crit Care Med. 2010;181:1217-1222.
26. Forslind K, Ahlmen M, Eberhardt K, et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004;63:1090-1095.
27. Forslind K, Hafstrom I, Ahlmen M, et al. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis. 2007;66:46-52.
28. Svensson B, Ahlmen M, Forslind K. Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options. Clin Exp Rheumatol 2003;21:327-332.
29. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
30. Ekdahl C, Eberhardt K, Andersson SI, et al. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol. 1988;17:263-271.
31. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
32. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845-1850.